Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
dimanche, octobre 25
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Inovio Pharmaceuticals Inc
INO
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.8971
0.0582
6.94%
Dern. MÀJ: Oct 23, 7:58 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Inovio Pharmaceuticals Financials
Inovio Pharmaceuticals (INO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Inovio Pharmaceuticals Q2 EPS $(0.07) Beats $(0.22) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.22) by 68.18 percent. This is a 88.52 percent increase over losses of $(0.61) per share
Benzinga Newsdesk
PRO
Inovio Pharmaceuticals Q1 EPS $(0.28) Beats $(0.36) Estimate, Sales $0.000 Miss $250.000K Estimate
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
INOVIO Pharmaceuticals Estimates Its Current Cash, Cash Equivalents And Short-Term Investments Balances To Support The Company's Operations Into Q4 2026; Projection Includes An Operational Net Cash Burn Estimate Of ~$22M For Q1 2026.
Benzinga Newsdesk
PRO
Inovio Pharmaceuticals Q4 EPS $(0.26) Beats $(0.38) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.38) by 31.22 percent. This is a 60 percent increase over losses of $(0.65) per share
Benzinga Newsdesk
Earnings Scheduled For March 12, 2026
Benzinga Insights
